Bio Innovation Conference | 2020 Agenda
10
page-template,page-template-full_width,page-template-full_width-php,page,page-id-10,page-parent,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive
 

2020 Agenda

OCTOBER 5+6, 2020 • VIRTUAL CONFERENCE

Monday, October 5, 2020

7:00 am – 7:00 pm
BIO One-on-One Partnering Meetings open
8:00 am – 5:00 pm
Exhibit Hall Open   |   Networking Lounge Open
9:00 am – 9:15 am

Welcome and Opening Remarks

Remarks by:
Martin Rosendale, CEO, Maryland Life Sciences, a division of Maryland Tech Council
Jeff Galvin, CEO and Founder, American Gene Technologies

9:15 am – 10:15 am

Keynote session and Lifetime Achievement Award presentation

Jim Greenwood, Former President and CEO, Biotechnology Innovation Organization (BIO)

Introductions by:
Rachel King, Co-Founder and CEO, GlycoMimetics, Inc.

10:15 am – 10:25 am
Break
10:25 am – 11:25 am
SESSION A

Life Sciences Track

Pandemic & Risk Mitigation: A focus on preparation & resiliency

Three Maryland biotech leaders discuss how to prepare for the unforeseen and what is needed to pivot for the future.

Moderator:
Linda Segal, Principal, The McCormick Group

Speakers:
William Hearl, Ph.D., Founder and CEO, Immunomic Therapeutics, Inc.
Anne Lindblad, Ph.D., Former President and CEO, The Emmes Company, LLC
John Trizzino, Executive Vice President, Chief Business Officer and Chief Financial Officer, Novavax

Entrepreneurship Track

It Takes an Ecosystem

It takes an ecosystem to generate and support entrepreneurial activities, but no two regional ecosystems are alike. A fertile entrepreneurial ecosystem is the sum of interconnected individuals, organizations and entities, a unique regional terroir that facilitates and nourishes entrepreneurial activities. Our panelists will discuss their own experience in the Biohealth Capital Region, what is unique about the Maryland ecosystem, how they have successfully leveraged local resources, tools and contacts to build and grow their business, and why they have done it in Maryland.

Moderator:
Rosemarie Truman, Founder and CEO, The Center for Advancing Innovation

Speakers:
Hansilla Alaigh, Director, External Development, Emergent BioSolutions
Angela Graham
, President and CEO, Quality Biological
John Mumm, Ph.D., President and CEO, Deka Biosciences

11:25  am – 11:35  am
Break
11:35 am – 12:35 pm
SESSION B

Life Sciences Track

Vaccine Development: Driving Partnerships in Maryland

This panel will discuss the work that each company is doing on the vaccine development front, and will highlight important partners and collaborators they have used or will be using along their path to bringing life-saving products to market.

Moderator:
Marian Ewell, Sc.D., Chief Scientific Innovations Officer, The Emmes Company

Speakers:
Subhendu Basu, Ph.D., Chief Operating Officer, Adaptive Phage Therapeutics
Syed Husain, Senior Vice President, CDMO Business Unit Head, Emergent BioSolutions
Helen Montag, Senior Director, Corporate Partnerships, Johns Hopkins Technology Ventures
Sally Mossman, Ph.D., VP, Head of R&D Center, US, GSK Vaccines

Entrepreneurship Track

Human Resource as Strategy – Building a Team to Ensure Success and to Attract Investors

As a company progresses forward, the strategy of hiring decisions becomes paramount to their success.  Value judgments must be made on how to prioritize the skills and experience necessary to attract investors. This session will discuss building a team to ensure success. It will focus on the key roles within startup companies, developing boards, what to look for when partnering with investors and other companies, and the shift of expertise when transitioning from an early stage company to a public company.

Moderator:
Sally Allain, MSc., MBA, Head of JLABS @ Washington, DC, Johnson & Johnson Innovation – JLABS

Speaker:
Ellen Hukkelhoven, Ph.D., Managing Director, Perceptive Advisors
Ken Mills, President and CEO, REGENXBIO, Inc.
Claire Leurent, Ph.D., MBA, Principal, Venture Investments, Johnson & Johnson Innovation

12:35 pm – 1:50 pm

Thought Leadership Lightning Rounds

  • Lightning Round 1 (12:35 PM to 12:50 PM)

“More Savings, More Research”
BIO Business Solutions

BIO Business Solutions is the largest cost savings purchasing program for the life sciences industry, operated by BIO and available to members of MTC.  BIO Business Solutions pools the purchasing power of thousands of life sciences companies across North America to negotiate for exclusive pricing and favorable terms on things like lab supplies, office supplies, insurance, and much more.  Learn how MTC member companies can leverage the BIO Business Solutions to stretch their funding or improve their bottom line.

  • Lightning Round 2 (12:50 PM to 1:05 PM)

“The Immunology Capital Next to the Nation’s Capital: Montgomery County, MD”
Montgomery County Economic Development Corporation (MCEDC)

The epicenter for translating knowledge into previously unimaginable treatments and cures can be found in Montgomery County, Maryland next to the nation’s capital.  From cell and gene therapies to vaccines, biologics and advanced biomanufacturing, global innovators with the most promising advancements in science and human health grow with us here in Maryland. In a state that’s home to the largest payer, researcher and regulator of healthcare products in the world (CMS, NIH, and FDA), Montgomery County offers access to 40,000 life sciences workers, 18 federal agency headquarters, and a prime location that features 3 international airports, extensive parkland and broad diversity in our schools and community.  These resources and our prime location make Montgomery County the perfect landing spot to grow and thrive.

  • Lightning Round 3 (1:05 PM to 1:20 PM)

“Maryland Scientific Market: A 10-Year Forecast”
Scheer Partners

A discussion about the expanding geography of the Maryland scientific market, major drivers, product types and cost over the next ten years.

  • Lightning Round 4 (1:20 PM to 1:35 PM)

“The Death of the Regulatory Barrier to Better Medicine”
American Gene Technologies

Does the development of effective drugs have to be incredibly expensive? Maybe not anymore. There is a new type of drug development emerging: Gene Therapy. The hallmark of gene therapy is the ability to edit or modify the drivers of disease at the most fundamental level, our genes. To put it simply, we now have the ability to replace a broken gene in your DNA. Those educated on the subject of gene therapy will argue that there are a thousand caveats to that sweeping statement, but those caveats are quickly eroding.

  • Lightning Round 5 (1:35 PM to 1:50 PM)

“Maintaining Continuity of Clinical Research in the era of COVID-19”
KAI Research, Inc.

COVID-19 has brought about an inflection point in our industry. Despite a brief initial slowdown in clinical trials, thousands of COVID-19 trials are on-going today, in addition to existing clinical trials. Continuing clinical research through this pandemic requires us to adopt different approaches. This session will enable you to understand what it takes to run clinical trials in this new context, where remote monitoring and virtual trials are no longer just industry buzzwords, but business as usual.

2:00 pm – 3:00 pm
Virtual Trade Delegation Panel Discussion

Regenerative Medicine & Cell Therapy Industry of Kanagawa, Japan 

JETRO New York Kanagawa Division

Kanagawa Prefecture is one of the most dynamic life science and biotechnology hubs in Japan, home to diverse companies working on regenerative cell therapy, pharmaceuticals manufacturing, and reagent manufacturing for testing and research.  This webinar will showcase the three hottest Kanagawa companies in the field of regenerative cell therapy: REPROCELL, Elixirgen Scientific, Inc. and Cyfuse Biomedical.  Their deep connection to Maryland, along with Kanagawa-Maryland ties, one of the oldest US-Japan cooperative relationships, have formed a strong foundation for collaboration.  Partnerships with Kanagawa affiliated companies can serve as a gateway for Maryland businesses to the vast and growing opportunities in Asian markets.

Moderator:
Chiyo Kobayashi, Co-CEO, Washington CORE

Speaker:
Shizuka Akieda, CEO, Cyfuse Biomedical
David Bunton, CEO, REPROCELL Europe Ltd.
Hitoshi Suzuki
, Director, Kanagawa Division, JETRO New York
Tetsuya Tanaka, Ph.D., Director of Molecular Biology, Elixirgen Scientific, Inc.

3:00 pm – 4:00 pm
Virtual Trade Delegation Panel Discussion

Global Victoria

Tuesday, October 6, 2020

7:00 am-7:00pm
BIO One-on-One Partnering Meetings open
8:00 am-5:00pm
Exhibit Hall Open   |   Networking Lounge Open
9:00 am – 10:00 am

Keynote Speaker

Senator Chris Van Hollen

10:00 am – 10:10 am
Break
10:10 am – 11:10 am
SESSION C

Life Sciences Track

Biomanufacturing in Maryland: Building a global footprint and maximizing the local ecosystem

The state of Maryland has over 2,700 life science firms and 500+ biotech companies. Approximately 20% of the world’s top influencers in vaccine development are in Maryland, while VC investments in life sciences companies continue to increase rapidly. In addition to the thousands of regionally anchored life sciences companies headquartered in Maryland, there are 78 federal labs driving research and innovation in the area, while many more are expanding operations in the state and advancing Maryland’s biomanufacturing footprint. This panel session will discuss biomanufacturing in the Maryland area and how the state has created a perfect formula for biomanufacturing success.

Introduction by Maryland Department of Commerce

Moderator
Curran Simpson, Chief Operations and Technology Officer, REGENXBIO

Speakers
Sean Kirk, Executive Vice President, Manufacturing and Technical Operations, Emergent BioSolutions
Tom Spitznagel, Senior Vice President, BioPharmaceutical Development and Manufacturing, Macrogenics
Aaron Vernon, Vice President, Engineering & Supply Chain, Autolus

 

Entrepreneurship Track

Business Resiliency for Survival and Success

Business resiliency generally implies an ability to handle unexpected, difficult situations: lack of funding, failed clinical trial, surprise FDA audit, loss of a key employee, a lawsuit, stagnant sales, etc.; but it can also mean preparedness for achieving expected goals: license in a product, raise funds, advance the product, sell the product or business, etc. In this session a panel of entrepreneurs will share advice on business resiliency based on their business experiences.

Moderator
Murat Kalayoglu, M.D., Ph.D., President and CEO, Cartesian Therapeutics, Inc.

Speakers
Pete Buzy, President, Gene Therapy, Catalent
Kazem Kazempour, Ph.D., President and CEO, Amarex Clinical Research
Michael Ruff, President and CEO, Creative Bio-Peptides

11:10 am – 11:20 am
Break
11:20 am – 12:20 pm
SESSION D

Life Sciences Track

Expanding Progress and Opportunities in Gene and Cell Therapy

Gene and cell therapies have accrued a track record of disease treatment, IPOs on Wall Street, and transactions to large Pharma.  Cures for blindness (Lebers), a deadly inherited neuronal disorder (SMA), inherited immunodeficiency (ACA-SCID and X-SCID), and cancers (AML and ALL) are early examples, but the pace of development is accelerating!  Don’t miss out on the most significant future opportunities for healthcare, investment, collaboration, and career growth.  Catch up on the “cutting-edge” with experts at this session.

Moderator:
Jeff Galvin, CEO and Founder, American Gene Technologies

Speaker:
Dawn Driscoll, MBA, Ph.D., GAICD, Chief Executive Officer, Cell Therapies Pty Ltd
Bill Enright
, CEO, Vaccitech
Jon Rowley, Ph.D., Founder and Chief Product Officer, RoosterBio

Entrepreneurship Track

The Government as a Customer

There are many challenges facing the biotech industry today.  The worldwide need for new and sophisticated healthcare products can sometimes be achieved through governmental funding sources, who are looking to solve national and international issues relating to disease, defense and future prosperity. Our panel of experts will share their experiences and how they succeeded in navigating the process, with a look from the inside—out. Don’t miss this highly informative and eye opening session.

Moderator:
Geoffrey Ling, M.D., Ph.D., CEO, On Demand Pharmaceuticals Inc

Speaker:
Captain Joseph Cohn, Ph.D., Chief, Research Program Division, Defense Health Agency
Michael Fitzpatrick, Ph.D., President, Cellphire Inc.
Michael Ehret, Director of Business Development, ASELL

12:20 pm – 12:40 pm
Break
12:40 pm – 1:55 pm

Thought Leadership Lightning Rounds

  • Lightning Round 1 (12:40 PM to 12:55 PM)
    Maryland Department of Commerce
  • Lightning Round 2 (12:55 PM to 1:10 PM)
2:00 pm – 3:00 pm
Virtual Trade Delegation Panel Discussion

Shaping Frontiers in Medical Research: New South Wales, Australia

Global NSW

New South Wales (NSW) is a desirable destination for clinical trials and a recognised leader in developing and delivering transformational medical treatment in both gene and cell therapy, and precision oncology through genomics and proteomics. Join our internationally recognised key opinion leaders for a panel discussion covering clinical trials capabilities, health system advantages and integration, and opportunities for partnership and investment.

Moderator:
Antonio Penna, M.D., Executive Director, Office for Health and Medical Research, NSW Health

Speaker:
Elizabeth Koff, Secretary, NSW Health

Anita van der Meer
, Manager, ClinicalTrialsNSW. OHMR

David Thomas, Director
, The Kinghorn Cancer Centre; Head, Cancer Theme, Garvan Institute of Medical Research; Chief Executive Officer, Australian Genomic Cancer Medicine Centre; Conjoint Professor, St Vincent’s Clinical School, Faculty of Medicine, UNSW

Michelle Haber
, Executive Director, Children’s Cancer Institute; Co-Head of Theme, Molecular Targets and Cancer Therapeutics; Group Leader, Experimental Therapeutics; Conjoint Professor, School of Women’s and Children’s Health, UNSW

Ian Alexander
, Head, Gene Therapy Research Unit, Sydney Children’s Hospitals Network and Children’s Medical Research Institute; Professor in Pediatrics and Molecular Medicine, University of Sydney; Senior Staff Specialist, Genetic Metabolic Diseases Service, The Children’s Hospital at Westmead

Monday, October 5, 2020

7:00 am – 7:00 pm
BIO One-on-One Partnering Meetings open
8:00 am – 5:00 pm
Exhibit Hall Open   |   Networking Lounge Open
9:00 am – 9:15 am

Welcome and Opening Remarks

Remarks by:
Martin Rosendale, CEO, Maryland Life Sciences, a division of Maryland Tech Council
Jeff Galvin, CEO and Founder, American Gene Technologies

9:15 am – 10:15 am

Keynote session and Lifetime Achievement Award presentation

Jim Greenwood, Former President and CEO, Biotechnology Innovation Organization (BIO)

Introductions by:
Rachel King, Co-Founder and CEO, GlycoMimetics, Inc.

10:15 am – 10:25 am
Break
10:25 am – 11:25 am
SESSION A

Life Sciences Track

Pandemic & Risk Mitigation: A focus on preparation & resiliency

Three Maryland biotech leaders discuss how to prepare for the unforeseen and what is needed to pivot for the future.

Moderator:
Linda Segal, Principal, The McCormick Group

Speakers:
William Hearl, Ph.D., Founder and CEO, Immunomic Therapeutics, Inc.
Anne Lindblad, Ph.D., Former President and CEO, The Emmes Company, LLC
John Trizzino, Executive Vice President, Chief Business Officer and Chief Financial Officer, Novavax

Entrepreneurship Track

It Takes an Ecosystem

It takes an ecosystem to generate and support entrepreneurial activities, but no two regional ecosystems are alike. A fertile entrepreneurial ecosystem is the sum of interconnected individuals, organizations and entities, a unique regional terroir that facilitates and nourishes entrepreneurial activities. Our panelists will discuss their own experience in the Biohealth Capital Region, what is unique about the Maryland ecosystem, how they have successfully leveraged local resources, tools and contacts to build and grow their business, and why they have done it in Maryland.

Moderator:
Rosemarie Truman, Founder and CEO, The Center for Advancing Innovation

Speakers:
Hansilla Alaigh, Director, External Development, Emergent BioSolutions
Angela Graham
, President and CEO, Quality Biological
John Mumm, Ph.D., President and CEO, Deka Biosciences

11:25  am – 11:35  am
Break
11:35 am – 12:35 pm
SESSION B

Life Sciences Track

Vaccine Development: Driving Partnerships in Maryland

This panel will discuss the work that each company is doing on the vaccine development front, and will highlight important partners and collaborators they have used or will be using along their path to bringing life-saving products to market.

Moderator:
Marian Ewell, Sc.D., Chief Scientific Innovations Officer, The Emmes Company

Speakers:
Subhendu Basu, Ph.D., Chief Operating Officer, Adaptive Phage Therapeutics
Syed Husain, Senior Vice President, CDMO Business Unit Head, Emergent BioSolutions
Helen Montag, Senior Director, Corporate Partnerships, Johns Hopkins Technology Ventures
Sally Mossman, Ph.D., VP, Head of R&D Center, US, GSK Vaccines

Entrepreneurship Track

Human Resource as Strategy – Building a Team to Ensure Success and to Attract Investors

As a company progresses forward, the strategy of hiring decisions becomes paramount to their success.  Value judgments must be made on how to prioritize the skills and experience necessary to attract investors. This session will discuss building a team to ensure success. It will focus on the key roles within startup companies, developing boards, what to look for when partnering with investors and other companies, and the shift of expertise when transitioning from an early stage company to a public company.

Moderator:
Sally Allain, MSc., MBA, Head of JLABS @ Washington, DC, Johnson & Johnson Innovation – JLABS

Speaker:
Ellen Hukkelhoven, Ph.D., Managing Director, Perceptive Advisors
Ken Mills, President and CEO, REGENXBIO, Inc.
Claire Leurent, Ph.D., MBA, Principal, Venture Investments, Johnson & Johnson Innovation

12:35 pm – 1:50 pm

Thought Leadership Lightning Rounds

  • Lightning Round 1 (12:35 PM to 12:50 PM)

“More Savings, More Research”
BIO Business Solutions

BIO Business Solutions is the largest cost savings purchasing program for the life sciences industry, operated by BIO and available to members of MTC.  BIO Business Solutions pools the purchasing power of thousands of life sciences companies across North America to negotiate for exclusive pricing and favorable terms on things like lab supplies, office supplies, insurance, and much more.  Learn how MTC member companies can leverage the BIO Business Solutions to stretch their funding or improve their bottom line.

  • Lightning Round 2 (12:50 PM to 1:05 PM)

“The Immunology Capital Next to the Nation’s Capital: Montgomery County, MD”
Montgomery County Economic Development Corporation (MCEDC)

The epicenter for translating knowledge into previously unimaginable treatments and cures can be found in Montgomery County, Maryland next to the nation’s capital.  From cell and gene therapies to vaccines, biologics and advanced biomanufacturing, global innovators with the most promising advancements in science and human health grow with us here in Maryland. In a state that’s home to the largest payer, researcher and regulator of healthcare products in the world (CMS, NIH, and FDA), Montgomery County offers access to 40,000 life sciences workers, 18 federal agency headquarters, and a prime location that features 3 international airports, extensive parkland and broad diversity in our schools and community.  These resources and our prime location make Montgomery County the perfect landing spot to grow and thrive.

  • Lightning Round 3 (1:05 PM to 1:20 PM)

“Maryland Scientific Market: A 10-Year Forecast”
Scheer Partners

A discussion about the expanding geography of the Maryland scientific market, major drivers, product types and cost over the next ten years.

  • Lightning Round 4 (1:20 PM to 1:35 PM)

“The Death of the Regulatory Barrier to Better Medicine”
American Gene Technologies

Does the development of effective drugs have to be incredibly expensive? Maybe not anymore. There is a new type of drug development emerging: Gene Therapy. The hallmark of gene therapy is the ability to edit or modify the drivers of disease at the most fundamental level, our genes. To put it simply, we now have the ability to replace a broken gene in your DNA. Those educated on the subject of gene therapy will argue that there are a thousand caveats to that sweeping statement, but those caveats are quickly eroding.

  • Lightning Round 5 (1:35 PM to 1:50 PM)

“Maintaining Continuity of Clinical Research in the era of COVID-19”
KAI Research, Inc.

COVID-19 has brought about an inflection point in our industry. Despite a brief initial slowdown in clinical trials, thousands of COVID-19 trials are on-going today, in addition to existing clinical trials. Continuing clinical research through this pandemic requires us to adopt different approaches. This session will enable you to understand what it takes to run clinical trials in this new context, where remote monitoring and virtual trials are no longer just industry buzzwords, but business as usual.

2:00 pm – 3:00 pm
Virtual Trade Delegation Panel Discussion

Regenerative Medicine & Cell Therapy Industry of Kanagawa, Japan 

JETRO New York Kanagawa Division

Kanagawa Prefecture is one of the most dynamic life science and biotechnology hubs in Japan, home to diverse companies working on regenerative cell therapy, pharmaceuticals manufacturing, and reagent manufacturing for testing and research.  This webinar will showcase the three hottest Kanagawa companies in the field of regenerative cell therapy: REPROCELL, Elixirgen Scientific, Inc. and Cyfuse Biomedical.  Their deep connection to Maryland, along with Kanagawa-Maryland ties, one of the oldest US-Japan cooperative relationships, have formed a strong foundation for collaboration.  Partnerships with Kanagawa affiliated companies can serve as a gateway for Maryland businesses to the vast and growing opportunities in Asian markets.

Moderator:
Chiyo Kobayashi, Co-CEO, Washington CORE

Speaker:
Shizuka Akieda, CEO, Cyfuse Biomedical
David Bunton, CEO, REPROCELL Europe Ltd.
Hitoshi Suzuki
, Director, Kanagawa Division, JETRO New York
Tetsuya Tanaka, Ph.D., Director of Molecular Biology, Elixirgen Scientific, Inc.

3:00 pm – 4:00 pm
Virtual Trade Delegation Panel Discussion

Global Victoria

Tuesday, October 6, 2020

7:00 am-7:00pm
BIO One-on-One Partnering Meetings open
8:00 am-5:00pm
Exhibit Hall Open   |   Networking Lounge Open
9:00 am – 10:00 am

Keynote Speaker

Senator Chris Van Hollen

10:00 am – 10:10 am
Break
10:10 am – 11:10 am
SESSION C

Life Sciences Track

Biomanufacturing in Maryland: Building a global footprint and maximizing the local ecosystem

The state of Maryland has over 2,700 life science firms and 500+ biotech companies. Approximately 20% of the world’s top influencers in vaccine development are in Maryland, while VC investments in life sciences companies continue to increase rapidly. In addition to the thousands of regionally anchored life sciences companies headquartered in Maryland, there are 78 federal labs driving research and innovation in the area, while many more are expanding operations in the state and advancing Maryland’s biomanufacturing footprint. This panel session will discuss biomanufacturing in the Maryland area and how the state has created a perfect formula for biomanufacturing success.

Introduction by Maryland Department of Commerce

Moderator
Curran Simpson, Chief Operations and Technology Officer, REGENXBIO

Speakers
Sean Kirk, Executive Vice President, Manufacturing and Technical Operations, Emergent BioSolutions
Tom Spitznagel, Senior Vice President, BioPharmaceutical Development and Manufacturing, Macrogenics
Aaron Vernon, Vice President, Engineering & Supply Chain, Autolus

 

Entrepreneurship Track

Business Resiliency for Survival and Success

Business resiliency generally implies an ability to handle unexpected, difficult situations: lack of funding, failed clinical trial, surprise FDA audit, loss of a key employee, a lawsuit, stagnant sales, etc.; but it can also mean preparedness for achieving expected goals: license in a product, raise funds, advance the product, sell the product or business, etc. In this session a panel of entrepreneurs will share advice on business resiliency based on their business experiences.

Moderator
Murat Kalayoglu, M.D., Ph.D., President and CEO, Cartesian Therapeutics, Inc.

Speakers
Pete Buzy, President, Gene Therapy, Catalent
Kazem Kazempour, Ph.D., President and CEO, Amarex Clinical Research
Michael Ruff, President and CEO, Creative Bio-Peptides

11:10 am – 11:20 am
Break
11:20 am – 12:20 pm
SESSION D

Life Sciences Track

Expanding Progress and Opportunities in Gene and Cell Therapy

Gene and cell therapies have accrued a track record of disease treatment, IPOs on Wall Street, and transactions to large Pharma.  Cures for blindness (Lebers), a deadly inherited neuronal disorder (SMA), inherited immunodeficiency (ACA-SCID and X-SCID), and cancers (AML and ALL) are early examples, but the pace of development is accelerating!  Don’t miss out on the most significant future opportunities for healthcare, investment, collaboration, and career growth.  Catch up on the “cutting-edge” with experts at this session.

Moderator:
Jeff Galvin, CEO and Founder, American Gene Technologies

Speaker:
Dawn Driscoll, MBA, Ph.D., GAICD, Chief Executive Officer, Cell Therapies Pty Ltd
Bill Enright
, CEO, Vaccitech
Jon Rowley, Ph.D., Founder and Chief Product Officer, RoosterBio

Entrepreneurship Track

The Government as a Customer

There are many challenges facing the biotech industry today.  The worldwide need for new and sophisticated healthcare products can sometimes be achieved through governmental funding sources, who are looking to solve national and international issues relating to disease, defense and future prosperity. Our panel of experts will share their experiences and how they succeeded in navigating the process, with a look from the inside—out. Don’t miss this highly informative and eye opening session.

Moderator:
Geoffrey Ling, M.D., Ph.D., CEO, On Demand Pharmaceuticals Inc

Speaker:
Captain Joseph Cohn, Ph.D., Chief, Research Program Division, Defense Health Agency
Michael Fitzpatrick, Ph.D., President, Cellphire Inc.
Michael Ehret, Director of Business Development, ASELL

12:20 pm – 12:40 pm
Break
12:40 pm – 1:55 pm

Thought Leadership Lightning Rounds

  • Lightning Round 1 (12:40 PM to 12:55 PM)
    Maryland Department of Commerce
  • Lightning Round 2 (12:55 PM to 1:10 PM)
2:00 pm – 3:00 pm
Virtual Trade Delegation Panel Discussion

Shaping Frontiers in Medical Research: New South Wales, Australia

Global NSW

New South Wales (NSW) is a desirable destination for clinical trials and a recognised leader in developing and delivering transformational medical treatment in both gene and cell therapy, and precision oncology through genomics and proteomics. Join our internationally recognised key opinion leaders for a panel discussion covering clinical trials capabilities, health system advantages and integration, and opportunities for partnership and investment.

Moderator:
Antonio Penna, M.D., Executive Director, Office for Health and Medical Research, NSW Health

Speaker:
Elizabeth Koff, Secretary, NSW Health

Anita van der Meer
, Manager, ClinicalTrialsNSW. OHMR

David Thomas, Director
, The Kinghorn Cancer Centre; Head, Cancer Theme, Garvan Institute of Medical Research; Chief Executive Officer, Australian Genomic Cancer Medicine Centre; Conjoint Professor, St Vincent’s Clinical School, Faculty of Medicine, UNSW

Michelle Haber
, Executive Director, Children’s Cancer Institute; Co-Head of Theme, Molecular Targets and Cancer Therapeutics; Group Leader, Experimental Therapeutics; Conjoint Professor, School of Women’s and Children’s Health, UNSW

Ian Alexander
, Head, Gene Therapy Research Unit, Sydney Children’s Hospitals Network and Children’s Medical Research Institute; Professor in Pediatrics and Molecular Medicine, University of Sydney; Senior Staff Specialist, Genetic Metabolic Diseases Service, The Children’s Hospital at Westmead